Moldova drops controversial 20% VAT hike on medicines
The Moldovan Ministry of Finance has abandoned its controversial proposal to increase the Value Added Tax (VAT) on medicines from 8% to 20%. Minister of Finance Andrian Gavriliță confirmed the retreat following warnings from health officials and business associations that the fiscal reform would destabilize the country's vulnerable medical infrastructure.
The decision materialized after Minister of Health Emil Ceban issued a negative review of the 2027 fiscal policy draft, stating that the tax surge would trigger an inflationary cascade.
Institutional pushback forces policy reversal
Gavriliță clarified that the initial legislative intent aimed to optimize resource redistribution within the healthcare sector rather than restrict public access to treatments. However, the Ministry of Finance chose not to enforce the measure in the absence of institutional consensus or implementation capacity from health authorities.
During a national radio broadcast, Health Minister Emil Ceban emphasized that the public hospital network and vulnerable demographics could not absorb the fiscal shock.
Former Health Minister Ala Nemerenco also aligned with the criticism, warning that elevating the VAT rate to 20% would compromise pharmaceutical market competition. She noted that importing high-cost medications for oncology and rare diseases would become financially unviable for local distributors.
Economic consensus on social impact
The political opposition and civil society strongly supported the withdrawal of the tax amendment. Lawmaker Dinu Plîngău publicly criticized the initial draft, stating that the fiscal burden would fall disproportionately on low-income citizens rather than wealthy demographics.
Furthermore, the American Chamber of Commerce in Moldova (AmCham) issued an official position warning that the tax increase would lead to an immediate surge in shelf prices.
AmCham noted that higher costs would compel low-income patients and senior citizens to delay treating minor ailments. This systemic delay would ultimately transfer a heavier financial burden onto public hospitals and the state medical insurance budget.
Translation by Iurie Tataru
